Conference reports

Paediatric studies at EACS: trends in antiretroviral use in the Madrid Cohort; life expectancy significantly increased HIV/HCV co-infected children since HAART; use of tenofovir in treatment experienced children; switching to lopinavir/r from double protease inhibitor regimen; once daily lopinavir/r, 3TC and abacavir; planned treatment interruptions in children

11 February 2006. Related: Conference reports, Paediatric care.

Efficacy of lopinavir/r in patients with advanced HIV (CD4 <25 cells/mm3)

11 February 2006. Related: Conference reports, Antiretrovirals.

Potential barriers to use of T-20: results from patient and physician interviews

11 February 2006. Related: Conference reports, Antiretrovirals.

Factors associated with sexual dysfunction in HIV patients

11 February 2006. Related: Conference reports, Side effects.

Decreased varicella zoster immunity in migrants from sub-Saharan Africa

11 February 2006. Related: Conference reports, Coinfections and complications.

Clinical experience of switching to atazanavir in the UK’s largest clinic

11 February 2006. Related: Conference reports, Antiretrovirals.

Replacing a PI with atazanavir: separating swans from ducklings?

11 February 2006. Related: Conference reports, Antiretrovirals.

TMC 125: some good and bad news

11 February 2006. Related: Conference reports, Antiretrovirals.

When to change a failing regimen: second-line and salvage strategies

11 February 2006. Related: Conference reports, Antiretrovirals.

Antiretrovirals and other stuff!

11 February 2006. Related: Conference reports, Antiretrovirals.

Heart disease in people with HIV

11 February 2006. Related: Conference reports.

Mortality trends: why people with HIV die (or don’t) today

11 February 2006. Related: Conference reports.

45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), 16-19 December 2005, Washington, USA

10 February 2006. Related: Conference reports.

Understanding TMC114 power against resistant HIV

10 February 2006. Related: Conference reports, Antiretrovirals.

New antiretroviral compounds at ICAAC: new PI brecanavir from GSK; maturation inhibitor PA-457; antiviral activity of monoclonal antibody; TNX-355 in treatment experienced patients

10 February 2006. Related: Conference reports, Antiretrovirals.

Comparison of pharmacokinetics of originator and generic liquid formulations and split tablets in Malawian children

10 February 2006. Related: Conference reports, Paediatric care.

African-Americans in ACTG 5095 had shorter time to virologic failure and grade 3/4 side effects

10 February 2006. Related: Conference reports, Side effects.

Predictors of insulin resistance in first year of therapy

10 February 2006. Related: Conference reports, Side effects.

Three measures confirm 144-week renal record of tenofovir

10 February 2006. Related: Conference reports, Antiretrovirals.

Low rash risk with efavirenz after nevirapine rash

10 February 2006. Related: Conference reports, Antiretrovirals.

7th Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, 13-16 November 2005, Dublin, Ireland

13 December 2005. Related: Conference reports.

Monitoring side effects in resource limited countries

13 December 2005. Related: Conference reports, Side effects.

Uridine supplement reverses thymidine-induced lipoatrophy

13 December 2005. Related: Conference reports, Side effects, Weight, diabetes, metabolic complications.

Pravastatin increases limb fat in HIV-positive patients with hypercholesterolaemia

13 December 2005. Related: Conference reports, Side effects, Weight, diabetes, metabolic complications.

Evidence that facial fat can return after switching from either d4T or AZT, to abacavir or tenofovir

13 December 2005. Related: Conference reports, Side effects, Weight, diabetes, metabolic complications.

Niacin has beneficial effect on lipids but no reduction in abdominal fat

13 December 2005. Related: Conference reports, Side effects, Weight, diabetes, metabolic complications.

Gluteal implants used to replace lost buttock fat

13 December 2005. Related: Conference reports, Side effects, Weight, diabetes, metabolic complications.

10th European AIDS Conference, 17-20 November 2005, Dublin, Ireland

13 December 2005. Related: Conference reports.

Pregnancy studies at EACS

13 December 2005. Related: Conference reports, Pregnancy.

Further Reports from 3rd IAS Conference on AIDS Pathogenesis and Treatment, Rio de Janeiro, Brazil, 24-27 July 2005

13 October 2005. Related: Conference reports.

Management of hepatitis C and B in HIV-coinfected individuals: an overview of studies presented at the 3rd IAS Conference

13 October 2005. Related: Conference reports, Hepatitis coinfection.

Highlights of HIV drug resistance studies presented at the 3rd IAS Conference

13 October 2005. Related: Conference reports, Drug resistance.

3rd IAS Conference on HIV Pathogenesis and Treatment, 24-27 July 2005, Rio de Janeiro, Brasil

14 September 2005. Related: Conference reports.

Adult male circumcision reduces transmission rates over 18 months comparable to a vaccine with 65% efficacy

14 September 2005. Related: Conference reports, HIV prevention and transmission.

Benefits of adding 4 or 7 days of AZT/3TC to single-dose nevirapine to prevent MTCT: further analysis from TOPS

14 September 2005. Related: Conference reports, Pregnancy.

New drugs in pregnancy: atazanavir; T20

14 September 2005. Related: Conference reports, Pregnancy.

Lopinavir/r use in children less than two years old – promising results despite low plasma levels

14 September 2005. Related: Conference reports, Paediatric care.

Favourable outcomes in children treated with HAART in the MSF programmes

14 September 2005. Related: Conference reports, Paediatric care.

Encouraging results with cut up generic fixed dose combination tablets in Uganda

14 September 2005. Related: Conference reports, Paediatric care.

Predictors of survival at three years follow up for HIV-infected children in Cote D’Ivoire

14 September 2005. Related: Conference reports, Paediatric care.

Benefit of maintaining the M184V mutation with 3TC monotherapy: final 48-week results

14 September 2005. Related: Conference reports, Antiretrovirals.

T20 (enfuvirtide) studies presented at Rio

14 September 2005. Related: Conference reports.

Strategies for salvage therapy

14 September 2005. Related: Conference reports, Antiretrovirals.

Antiviral activity of foscarnet in salvage patients

14 September 2005. Related: Conference reports, Antiretrovirals.

Novel strategies with existing drugs

14 September 2005. Related: Conference reports, Antiretrovirals.

Antiretroviral activity of new and novel agents

14 September 2005. Related: Conference reports, Antiretrovirals.

Overview of pharmacology studies

14 September 2005. Related: Conference reports, PK and drug interactions.

Incidence of TB infection despite HAART and treatment in coinfected patients

14 September 2005. Related: Conference reports, TB coinfection.

Evaluation of ESAT-6 and CFP-10 as markers for response to TB treatment in HIV/TB coinfected patients

14 September 2005. Related: Conference reports, TB coinfection.

Does WHO clinical stage reliably predict who should receive ARV treatment?

14 September 2005. Related: Conference reports, Treatment access.

Continuous vs intermittent treatment with triple nuke combination of AZT/3TC/tenofovir in Africa: early results from DART study

14 September 2005. Related: Conference reports, Treatment access.

3rd IAS Conference on HIV Pathogenesis and Treatment, 24-27 July 2005, Rio de Janeiro, Brasil

14 August 2005. Related: Conference reports.

Keystone vaccine symposia 2005: vaccines, pathogenesis, snow and a couple of elk

14 August 2005. Related: Conference reports, Vaccines and microbicides.

14th International HIV Drug Resistance Workshop (14th IHDRW), 7-11 June 2005, Quebec City, Canada

15 July 2005. Related: Conference reports.

Genetic factors affecting HIV infection and progression rates: immunological factors relating to entry inhibitors

15 July 2005. Related: Conference reports, Basic science and immunology.

Resistance during MTCT strategies: new data on protective benefit of Combivir added to single-dose nevirapine, and impact of treatment and breastfeeding on the infant

15 July 2005. Related: Conference reports, Pregnancy.

Reduced replicative capacity of M184V explains benefit of 3TC monotherapy compared to stopping all drugs

14 July 2005. Related: Conference reports, Antiretrovirals.

Interaction between tenofovir and ddI in triple-nucleoside combinations: role of M184V in explaining resistance on failure

14 July 2005. Related: Conference reports, Drug resistance.

Predicting clinical responses to ddI from genotypic resistance

14 July 2005. Related: Conference reports, Drug resistance.

Under-detection of transmission of transmitted resistance and impact on treatment response

14 July 2005. Related: Conference reports, Drug resistance.

Risk of death in UK after diagnosis of 3-class resistance

14 July 2005. Related: Conference reports, Drug resistance.

11th BHIVA and BASSH joint annual conference, 22-25 April 2005, Dublin

15 June 2005. Related: Conference reports.

Long-awaited UK pregnancy guidelines now updated; pregnancy studies in Dublin

15 June 2005. Related: Conference reports, Pregnancy.

Underdosing of ARVs in children: results from CHIPS cohort

15 June 2005. Related: Conference reports, Paediatric care.

Sexual transmission and response to treatment in acute HCV infection in HIV-positive gay men coinfected with HIV

15 June 2005. Related: Conference reports, Hepatitis coinfection.